TAPIR study shows that GPA patients treated with rituximab can be safely weaned off low dose prednisone. But. 20% risk of relapse in those treated with non-RTX regimens ⁦@VasculitisBCN24⁩ #vasculitis https://t.co/jDy0lOQQIP